20 May 2004
Treatment of acute renal failure (ARF) and oliguria/anuria in three prematurely delivered infants with fenoldopam – three cases report
Ryszard Lauterbach, Dorota Pawlik, Joanna WoźniakMed Sci Monit 2004; 10(2): 109-111 :: ID: 11849
Abstract
Background: Fenoldopam – a dopamine analogue - stimulates postsynaptic D1 receptors in the renal and splanchnic circulatory vessels and has no activity on D2 receptors, α and β adrenergic receptors. It increases RBF and urine output, without significant changes in the blood pressure.Due to those effects, we decided to use fenoldopam in the treatment of infants undergoing acute renal failure in oliguric state.Case Report: We present the schedule of the therapy of three premature newborns, whom we administered fenoldopam (dose 0.1 µg × kg–1 × min–1) in ARF. We observed the improvement in kidney function and urinary output. The first patient suffered from ARF secondary to SIRS and the abdominal aortic embolism. A recovery of renal function and improvement of clinical state have been observed after introduction of a complex therapy including fenoldopam).Next patient developed ARF on the third day after delivery. The inborn infection, hepatic failure, and dyspnoea have accompanied ARF. Although he was given a complete treatment and fenoldopam infusion leading to increase in diuresis, he died in the course of DIC.In the third infant sepsis was the cause of arising ARF on 19th day of life. Two days of using fenoldopam resulted in enlarging urinary output and return of renal function.Conclusions: The normalisation of renal parameters depended on the combination of traditional methods of therapy with the administration of fenoldopam. The positive effects of the therapy indicate the safety of usage and proposed dosage of fenoldopam in infants and should be verified in further studies.
Keywords: fenoldopam, acute renal failure, Sepsis, neonate
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952